Richard Klausner, Director at Juno Therapeutics, Inc. (JUNO), sold 12,000 shares at $45.74 ($549K) on 2015-12-15, disclosed to the SEC on 2015-12-17.
Scheduled sale ($549k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.81 | 4,215 | $189K | 34.4% |
| 2 | $45.74 | 3,700 | $169K | 30.9% |
| 3 | $46.62 | 4,085 | $190K | 34.7% |
| Total | $45.71 avg | 12,000 | $549K | 100% |
| Filing → |
| LYEL | SELL | 2022-09-27 | $71K | — | Filing → |
| JUNO | SELL | 2018-01-09 | $1.2M | — | Filing → |
| JUNO | SELL | 2017-12-22 | $3.2M | — | Filing → |